IB2000

IB2000 is an investigational drug series being developed by IntraBio Inc., a biopharmaceutical company focused on treatments for rare and common neurodegenerative and lysosomal storage diseases. The IB2000 series is specifically targeted toward the treatment of otorhinolaryngologic diseases, which encompass disorders of the ear, nose, and throat. The development of this asset leverages IntraBio's proprietary platform technologies that focus on the modulation of lysosomal function and intracellular calcium signaling, based on research from the University of Oxford and the University of Munich. While specific details regarding the active pharmaceutical ingredient and molecular targets are not yet publicly disclosed, the series is part of a broader pipeline of small molecule candidates designed to address pathologies related to cellular trafficking and ion homeostasis.